Filing Overview
NLS Pharmaceutics Ltd. filed a Form 6-K on January 23, 2023, covering January 2023 (Report No. 4). The filing concerns an extraordinary shareholder meeting scheduled for February 15, 2023. The filing identifies the registrant as NLS Pharmaceutics Ltd., not Newcelx Ltd.
Business Context and Reporting Period
- Foreign private issuer filing under Form 6-K; the registrant files annual reports on Form 20-F.
- Shareholders of record as of January 31, 2023, are entitled to vote at the meeting and any postponement or adjournment.
- The filing attaches a notice of meeting and proxy card as Exhibit 99.1.
Financial and Operating Information
The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes, Outlook, and Risks
The filing does not disclose material financial or operating changes, management guidance, business outlook, contingencies, or specific risks. Its stated purpose is to furnish shareholder-meeting materials.
Investor Verification Items
- Confirm the issuer identity, because the request metadata names Newcelx Ltd., while the filing names NLS Pharmaceutics Ltd.
- Review Exhibit 99.1 for the meeting agenda, proposed resolutions, voting procedures, and any transaction or corporate-action details.
- Verify the January 31, 2023 record date and February 15, 2023 meeting date.
- Check subsequent SEC filings for the meeting results and any disclosures that supersede or supplement this report.